The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Benefit from B-Lymphocyte Depletion Using the Anti-CD20 Antibody Rituximab in Chronic Fatigue Syndrome. A Double-Blind and Placebo-Controlled Study
Open accessAbstract
BACKGROUND: Chronic fatigue syndrome (CFS) is a disease of unknown aetiology. Major CFS symptom relief during cancer chemotherapy in a patient with synchronous CFS and lymphoma spurred a pilot study of B-lymphocyte depletion using the anti-CD20 antibody Rituximab, which demonstrated significant clinical response in three CFS patients. METHODS AND FINDINGS: In this double-blind, placebo-controlled phase II study (NCT00848692), 30 CFS patients were randomised to either Rituximab 500 mg/m(2) or saline, given twice two weeks apart, with follow-up for 12 months. Xenotropic murine leukemia virus-related virus (XMRV) was not detected in any of the patients. The responses generally affected all CFS symptoms. Major or moderate overall response, defined as lasting improvements in self-reported Fatigue score during follow-up, was seen in 10 out of 15 patients (67%) in the Rituximab group and in two out of 15 patients (13%) in the Placebo group (p = 0.003). Mean response duration within the follow-up period for the 10 responders to Rituximab was 25 weeks (range 8-44). Four Rituximab patients had clinical response durations past the study period. General linear models for repeated measures of Fatigue scores during follow-up showed a significant interaction between time and intervention group (p = 0.018 for self-reported, and p = 0.024 for physician-assessed), with differences between the Rituximab and Placebo groups between 6-10 months after intervention. The primary end-point, defined as effect on self-reported Fatigue score 3 months after intervention, was negative. There were no serious adverse events. Two patients in the Rituximab group with pre-existing psoriasis experienced moderate psoriasis worsening. CONCLUSION: The delayed responses starting from 2-7 months after Rituximab treatment, in spite of rapid B-cell depletion, suggests that CFS is an autoimmune disease and may be consistent with the gradual elimination of autoantibodies preceding clinical responses. The present findings will impact future research efforts in CFS. TRIAL REGISTRATION: ClinicalTrials.gov NCT00848692.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Lombardi, V. C., Ruscetti, F. W., Das Gupta, J., Pfost, M. A., Hagen, K. S., Peterson, D. L., Ruscetti, S. K., Bagni, R. K., Petrow-Sadowski, C., Gold, B., et al. (2009) · Science · doi:10.1126/science.1179052 · Cited by 538
RetractedThe Chronic Fatigue Syndrome: A Comprehensive Approach to Its Definition and Study
Fukuda, K., Straus, S. E., Hickie, I., Sharpe, M. C., Dobbins, J. G., Komaroff, A., & and International Chronic Fatigue Syndrome Study Group. (1994) · Annals of Internal Medicine · doi:10.7326/0003-4819-121-12-199412150-00009 · Cited by 4,969
Carruthers, B. M., Jain, A. K., De Meirleir, K. L., Peterson, D. L., Klimas, N. G., Lerner, A. M., Bested, A. C., Flor-Henry, P., Joshi, P., Powles, A. C. P., et al. (2003) · Journal of Chronic Fatigue Syndrome · doi:10.1300/j092v11n01_02 · Cited by 1,180
Pace, T. W. W., & Heim, C. M. (2011) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2010.10.003 · Cited by 321
Nacul, L. C., Lacerda, E. M., Pheby, D., Campion, P., Molokhia, M., Fayyaz, S., Leite, J. C., Poland, F., Howe, A., & Drachler, M. L. (2011) · BMC Medicine · doi:10.1186/1741-7015-9-91 · Cited by 255
Recombinant Origin of the Retrovirus XMRV
Paprotka, T., Delviks-Frankenberry, K. A., Cingöz, O., Martinez, A., Kung, H.-J., Tepper, C. G., Hu, W.-S., Fivash, M. J., Coffin, J. M., & Pathak, V. K. (2011) · Science · doi:10.1126/science.1205292 · Cited by 240
A formal analysis of cytokine networks in chronic fatigue syndrome
Broderick, G., Fuite, J., Kreitz, A., Vernon, S. D., Klimas, N., & Fletcher, M. A. (2010) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2010.04.012 · Cited by 202
Cited by
Cytokine signature associated with disease severity in chronic fatigue syndrome patients
Montoya, J. G., Holmes, T. H., Anderson, J. N., Maecker, H. T., Rosenberg-Hasson, Y., Valencia, I. J., Chu, L., Younger, J. W., Tato, C. M., & Davis, M. M. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1710519114 · Cited by 402
Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A Comprehensive Review
Cortes Rivera, M., Mastronardi, C., Silva-Aldana, C., Arcos-Burgos, M., & Lidbury, B. (2019) · Diagnostics · doi:10.3390/diagnostics9030091 · Cited by 313
Chronic viral infections in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS)
the European Network on ME/CFS (EUROMENE), Rasa, S., Nora-Krukle, Z., Henning, N., Eliassen, E., Shikova, E., Harrer, T., Scheibenbogen, C., Murovska, M., & Prusty, B. K. (2018) · Journal of Translational Medicine · doi:10.1186/s12967-018-1644-y · Cited by 312
Myalgic Encephalomyelitis/Chronic Fatigue Syndrome – Evidence for an autoimmune disease
Sotzny, F., Blanco, J., Capelli, E., Castro-Marrero, J., Steiner, S., Murovska, M., & Scheibenbogen, C. (2018) · Autoimmunity Reviews · doi:10.1016/j.autrev.2018.01.009 · Cited by 272
Distinct plasma immune signatures in ME/CFS are present early in the course of illness
Hornig, M., Montoya, J. G., Klimas, N. G., Levine, S., Felsenstein, D., Bateman, L., Peterson, D. L., Gottschalk, C. G., Schultz, A. F., Che, X., et al. (2015) · Science Advances · doi:10.1126/sciadv.1400121 · Cited by 263
Metadata
- Authors
- Fluge, Ø., Bruland, O., Risa, K., Storstein, A., Kristoffersen, E. K., Sapkota, D., Næss, H., Dahl, O., Nyland, H., & Mella, O.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2011-10-19
- Volume
- 6
- Issue
- 10
- Pages
- e26358
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W2041818093
- Cited by
- 194
- References
- 7
- FWCI
- 8.27
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Benefit from B-Lymphocyte Depletion Using the Anti-CD20 Antibody Rituximab in Chronic Fatigue Syndrome. A Double-Blind and Placebo-Controlled Study. https://app.cochat.ai/papers/10.1371/journal.pone.0026358
- The paper
- Fluge, Ø., Bruland, O., Risa, K., Storstein, A., Kristoffersen, E. K., Sapkota, D., Næss, H., Dahl, O., Nyland, H., & Mella, O. (2011). Benefit from B-Lymphocyte Depletion Using the Anti-CD20 Antibody Rituximab in Chronic Fatigue Syndrome. A Double-Blind and Placebo-Controlled Study. PLoS ONE. https://doi.org/10.1371/journal.pone.0026358
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.